Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90.4M
-
Number of holders
-
431
-
Total 13F shares, excl. options
-
42.6M
-
Shares change
-
-4.45M
-
Total reported value, excl. options
-
$5.2B
-
Value change
-
-$577M
-
Put/Call ratio
-
1.19
-
Number of buys
-
269
-
Number of sells
-
-159
-
Price
-
$121.85
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q1 2021
538 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q1 2021.
CRISPR Therapeutics AG - Common Stock (CRSP) has 431 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42.6M shares
of 90.4M outstanding shares and own 47.15% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (8.29M shares), Capital International Investors (4.87M shares), Nikko Asset Management Americas, Inc. (3.66M shares), NEA Management Company, LLC (1.59M shares), Versant Venture Management, LLC (1.55M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.3M shares), BlackRock Inc. (1.29M shares), TWO SIGMA INVESTMENTS, LP (1.14M shares), WADDELL & REED FINANCIAL INC (1.07M shares), and TWO SIGMA ADVISERS, LP (1.03M shares).
This table shows the top 431 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.